CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic.
The US FDA has approved Pfizer and Moderna's two vaccines for sale in the US market. The scientific community is still trying to understand the virus in many ways and compile useful data. The virus uses the spike protein (S protein) to bind angiotensin-converting enzyme 2 (ACE-2) to cause infection. S protein is a highly glycosylated protein with 22 N-linked and 3 O-linked glycosylation sites. It is a key protein that affects virus infection and vaccine preparation. Therefore, it has become the focus of attention in academia and industry.
To help scientists around the world to better study SARS-CoV-2, CD BioGlyco integrates its most advanced technology platforms and do its best to promote coronavirus research. The following services are now available at CD BioGlyco for customers to choose:
To know more about the SARS-CoV-2 Glycosylation Profiling service at CD BioGlyco, please visit https://www.bioglyco.com/sars-cov-2-glycosylation-profiling.html.